Join
Live feed
·
PRReleasevia Quantisnow
Sionna Therapeutics Inc. logo

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
SION· Sionna Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SION (Sionna Therapeutics Inc.) and more on Quantisnow.